Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epratuzumab-cys-tesirine - ADC therapeutics

Next Previous
Drug Profile

Epratuzumab-cys-tesirine - ADC therapeutics

Alternative Names: ADCT-602; Epratuzumab-cys-SG3249; hLL2-cys-PBD; hLL2-cys-SG3249

Latest Information Update: 28 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ADC Therapeutics
  • Class Antineoplastics; Benzodiazepines; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies; Pyrroles
  • Mechanism of Action DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Precursor B-cell lymphoblastic leukaemia-lymphoma
  • No development reported B-cell lymphoma

Most Recent Events

  • 28 Jan 2025 No recent reports of development identified for preclinical development in B-cell lymphoma in Switzerland (Parenteral)
  • 10 Dec 2022 Efficacy and adverse events data from a phase I/II trial in Precursor B-cell lymphoblastic leukaemia-lymphoma presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)
  • 11 Dec 2021 Safety, efficacy and pharmacokinetics data from a phase I/II trial in Precursor B-cell lymphoblastic leukaemia-lymphoma presented at the 63rd American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2021)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top